Blindness News and Research

RSS

Clinica of Virginia offers medical services to Medicare and Medicaid patients for $1.00

In an effort to promote wellness and help those who are struggling to make ends meet, Clinica of Virginia, LLC. is providing quality medical services to Medicare and Medicaid patients for only $1.00. The national economic downturn, combined with national bureaucracy, has created a shortage of physicians and clinics who accept Medicare and Medicaid. Chronic, multiple medical conditions plague those Americans who can financially afford it the least, and physicians' offices who accept Medicare or Medicaid are now far and few between. Clinica accepts both.

10 Sep 2010

Researchers investigate familial prosopagnosia to recognize faces

In our dynamic 3D world, we can encounter a familiar face from any angle and still recognize that face with ease, even if the person has, for example, changed his hair style. This is because our brain has used the 2D snapshots perceived by our eyes (like a camera) to build and store a 3D mental representation of the face, which is resilient to such changes.

9 Sep 2010

Promedior initiates PRM-151 Phase 2a clinical study in prevention of scarring post glaucoma filtration surgery

Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat fibrotic and inflammatory diseases, announced today that it has initiated a Phase 2a clinical study of PRM-151 to evaluate the efficacy, safety, and tolerability of PRM-151 in preventing post-surgical scarring in glaucoma patients following glaucoma filtration surgery. There currently are no approved drugs for preventing post-surgical scarring in glaucoma, and there are no approved anti-fibrotic drug therapies in the U.S. or Europe for any fibrotic disease.

7 Sep 2010

Microplasmin MIVI-TRUST Phase III program's positive pooled results presented at EURETINA

ThromboGenics NV, a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, cardiovascular disease and cancer, announces that the pooled results from the successful microplasmin MIVI-TRUST Phase III program were presented today at the EURETINA (European Society of Retina Specialists) Congress in Paris, France.

6 Sep 2010

UB symposium to discuss in silico molecular design, high-throughput screening to treat diseases

Twenty-first-century pharmaceutical breakthroughs require 21st-century drug discovery tools, such as computational or in silico molecular design and high-throughput screening of effective, new compounds. That's the theme of a University at Buffalo symposium to be held Sept. 11 on "Twenty-first Century Bioscience: In Silico Methods and High-Throughput Screening," which will feature a variety of cutting-edge advances in the field developed by researchers in Western New York and throughout the US.

3 Sep 2010

Alcon to launch AcrySof IQ ReSTOR Multifocal Toric intraocular lens outside US during 2010 ESCRS meeting

Alcon, Inc., the world's leader in eye care and cataract surgery, announced its launch of the AcrySof® IQ ReSTOR® Multifocal Toric intraocular lens (IOL) outside the United States during the 2010 European Society of Cataract and Refractive Surgeons (ESCRS) annual meeting in Paris, France. This new lens is built on Alcon's industry leading AcrySof® platform and is designed to provide cataract patients that have astigmatism a surgical option that delivers quality vision at all distances with increased spectacle independence.

3 Sep 2010

ThromboGenics second microplasmin Phase III trial for non-surgical treatment of VMA meets primary endpoint

ThromboGenics NV, a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, vascular disease and cancer announces that its second Phase III trial evaluating microplasmin for the non-surgical treatment of vitreomacular adhesion (VMA) has met its primary endpoint.

2 Sep 2010

FDA approves LUMIGAN eye drops for intraocular pressure reduction in open-angle glaucoma patients

Allergan, Inc. today announced the United States Food and Drug Administration (FDA) has approved LUMIGAN (bimatoprost ophthalmic solution) 0.01% as a first-line therapy indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

2 Sep 2010

FDA grants Priority Review status to Alimera Sciences' Iluvien for diabetic macular edema

Alimera Sciences, Inc.,, a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced today that the Company's New Drug Application (NDA) for Iluvien® (fluocinolone acetonide intravitreal insert) has been accepted for filing and granted Priority Review status by the U.S. Food and Drug Administration (FDA).

31 Aug 2010

Researcher develops new plaque brachytherapy technique to treat eye cancer

Rare but devastating, eye cancer can strike anyone at any time and treating it often requires radiation that leaves half of all patients partially blind.But a new technique developed by Scott Oliver, MD, assistant professor at the University of Colorado School of Medicine, may change all that.

30 Aug 2010

World's tallest man undergoes Gamma Knife surgery

Much of Sultan Kosen's eight feet, two-inch stature rose up in an 17-year period starting at age 10, when the benign tumor in his brain's pituitary gland highjacked the organ, causing it to secrete massive amounts of growth hormone, making Mr. Kosen's body grow fast and grow without ceasing. He will need to wait several months to find out if his Gamma Knife® surgery last Thursday at the University of Virginia (UVA, Charlottesville, Va.) has inactivated the tumor and he has reached his final height, but his physicians are optimistic.

27 Aug 2010

New article examines education practices, priorities for deaf-blind children

Deaf-blind children can be isolated and disconnected from people and activities. Without individualized support, they cannot access visual and auditory information and often complete school unable to seek future education, employment, or independent living. Providing appropriate special education and related services for deaf-blind children poses unique challenges.

26 Aug 2010

Tree Top enters Letter of Intent with WorldWithoutBlindness

Recently Tree Top, entered into a Letter of Intent with WorldWithoutBlindness, LLC, ("WWB"), a not-for-profit medical corporation whose expressed mission is "to prevent blindness through screening and early disease detection, patient information, physician education and vision science research." During due diligence, Tree Top's management, along with WWB related medical staff, identified that more work needed to be done to successfully implement WWB's business model.

26 Aug 2010

Researchers show biosynthetic cornea can stimulate regeneration in damaged eye tissue

A new study from researchers in Canada and Sweden has shown that biosynthetic corneas can help regenerate and repair damaged eye tissue and improve vision in humans.

26 Aug 2010

FibroGen announces study results of recombinant human type III collagen in corneal damage

FibroGen, Inc., today announced results of a 2-year clinical study demonstrating that surgical implantation of biosynthetic corneas formulated with the company's proprietary recombinant human type III collagen (rhCIII) restored vision and promoted nerve regeneration (restoring sensitivity) in patients who had corneal damage and significant vision loss.

26 Aug 2010

Gene linked to Fuchs corneal dystrophy discovered

A 13-member research team led by University of Oregon scientist Dr. Albert O. Edwards has found a gene likely responsible for Fuchs corneal dystrophy, an inheritable genetic disorder and leading cause of corneal transplant operations.

26 Aug 2010

Special empowerment program to promote confidence in diabetic children

Teens are learning how to shred down the mountain and balance blood sugars in a special empowerment program called Riding on Insulin, taking place December 11, 2010, at The Canyons Resort in Park City. The day, led by Sean Busby,26 year old professional snowboarder with type 1 diabetes promotes courage and confidence and shows children with type 1 or type 2 they can overcome mental and physical challenges.

24 Aug 2010

Raptor Pharmaceutical updates on cysteamine bitartrate Phase 3 clinical trial in cystinosis patients

Raptor Pharmaceutical Corp.,provides updates on timelines related to its clinical programs including the pivotal Phase 3 clinical trial of its proprietary delayed-release oral formulation of cysteamine bitartrate ("DR Cysteamine") in patients with nephropathic cystinosis ("cystinosis").

24 Aug 2010

Merck and Bill & Melinda Gates Foundation commit additional $60M to support Botswana's ACHAP

Merck today announced the Merck Company Foundation and the Bill & Melinda Gates Foundation are committing an additional $60 million to support Botswana's African Comprehensive HIV/AIDS Partnerships (ACHAP). Merck is known as MSD outside the US and Canada. A unique program developed with and led by the Government of Botswana, ACHAP is one of sub-Saharan Africa's oldest, most successful public-private partnerships.

24 Aug 2010

Study finds evidence that single-disease initiatives may compromise fragile health systems in low-income countries

Single-disease initiatives in low-income countries with fragile health systems may compromise the ability of such health systems to meet the other community needs, according to a study published Tuesday in PLoS Neglected Tropical Diseases, VaccineNewsDaily.com reports (Purlain, 8/18).

20 Aug 2010

Blindness News and Research

Clinica of Virginia offers medical services to Medicare and Medicaid patients for $1.00

Researchers investigate familial prosopagnosia to recognize faces

Promedior initiates PRM-151 Phase 2a clinical study in prevention of scarring post glaucoma filtration surgery

Microplasmin MIVI-TRUST Phase III program's positive pooled results presented at EURETINA

UB symposium to discuss in silico molecular design, high-throughput screening to treat diseases

Alcon to launch AcrySof IQ ReSTOR Multifocal Toric intraocular lens outside US during 2010 ESCRS meeting

ThromboGenics second microplasmin Phase III trial for non-surgical treatment of VMA meets primary endpoint

FDA approves LUMIGAN eye drops for intraocular pressure reduction in open-angle glaucoma patients

FDA grants Priority Review status to Alimera Sciences' Iluvien for diabetic macular edema

Researcher develops new plaque brachytherapy technique to treat eye cancer

World's tallest man undergoes Gamma Knife surgery

New article examines education practices, priorities for deaf-blind children

Tree Top enters Letter of Intent with WorldWithoutBlindness

Researchers show biosynthetic cornea can stimulate regeneration in damaged eye tissue

FibroGen announces study results of recombinant human type III collagen in corneal damage

Gene linked to Fuchs corneal dystrophy discovered

Special empowerment program to promote confidence in diabetic children

Raptor Pharmaceutical updates on cysteamine bitartrate Phase 3 clinical trial in cystinosis patients

Merck and Bill & Melinda Gates Foundation commit additional $60M to support Botswana's ACHAP

Study finds evidence that single-disease initiatives may compromise fragile health systems in low-income countries

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News